AstraZeneca's statin Crestor shows efficacy in new atherosclerosis study
Anglo-Swedish pharmaceutical major AstraZeneca says that data from a long-term trial of its drug Crestor (rosuvastatin) has demonstrated its ability to reverse plaque build-up in patients with coronary artery disease. The results, which were presented at the 55th annual scientific session of the American College of Cardiology meeting in Atlanta, are derived from the ASTEROID (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound Derived Coronary Atheroma Burden) program.
Atherosclerosis occurs when deposits of fatty substances, cholesterol or cellular waste products collect in the inner lining of an artery-forming a plaque build up which can block the flow of blood to the heart or brain.
Crestor description and history
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze